Table 6.
Arm/Shoulder Pain
| None | A little | Quite a bit | Very Much | p-value (little+) | p-value (quite a bit+) | ||
|---|---|---|---|---|---|---|---|
|
| |||||||
| POST OP | Overall Arm/Shoulder Pain (N=321) | 118 (36.8%) | 148 (46.1%) | 45 (14.0%) | 10 (3.1%) | ||
|
| |||||||
| Vs Arm (N=321) | 0.218 | 0.656 | |||||
| CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=67) | 19 (28.4%) | 34 (50.8%) | 14 (20.9%) | 0 (0%) | |||
| AC (Doxorubicin and Cyclophosphamide) (N=99) | 36 (36.4%) | 47 (47.5%) | 14 (14.1%) | 2 (2.0%) | |||
| Capecitabine (N=155) | 63 (40.6%) | 67 (43.2%) | 17 (11.0%) | 8 (5.2%) | |||
|
| |||||||
| Vs Most Extensive Surgery (N=319) | 0.834 | 0.276 | |||||
| Breast Conserving Surgery (N=143) | 52 (36.4%) | 70 (49.0%) | 17 (11.9%) | 4 (2.8%) | |||
| Full Mastectomy (N=176) | 66 (37.5%) | 76 (43.2%) | 28 (15.9%) | 6 (3.4%) | |||
|
| |||||||
| Vs Axillary Dissection (N=321) | <0.001 | 0.009 | |||||
| No (N=65) | 37 (56.9%) | 24 (36.9%) | 4 (6.2%) | 0 (0%) | |||
| Yes (N=256) | 81 (31.6%) | 124 (48.4%) | 41 (16.0%) | 10 (3.9%) | |||
|
| |||||||
| Vs RT (N=300) | 0.112 | 0.397 | |||||
| No (N=139) | 59 (42.4%) | 60 (43.2%) | 15 (10.8%) | 5 (3.6%) | |||
| Yes (N=161) | 54 (33.5%) | 78 (48.4%) | 25 (15.5%) | 4 (2.5%) | |||
|
| |||||||
| Vs Number of Nodes Examined (N=314) | <0.001 | 0.087 | |||||
| 0-3 (N=49) | 25 (51.0%) | 18 (36.7%) | 6 (12.2%) | 0 (0%) | |||
| 4-7 (N=53) | 28 (52.8%) | 20 (37.7%) | 5 (9.4%) | 0 (0%) | |||
| 8+ (N=212) | 62 (29.2%) | 106 (50.0%) | 34 (16.0%) | 10 (4.7%) | |||
|
| |||||||
| AT 12 MONTHS | Overall Arm/Shoulder Pain (N=259) | 133 (51.4%) | 96 (37.1%) | 22 (8.5%) | 8 (3.1%) | ||
|
| |||||||
| Vs Arm (N=259) | 0.514 | 0.274 | |||||
| CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=54) | 24 (44.4%) | 24 (44.4%) | 5 (9.3%) | 1 (1.9%) | |||
| AC (Doxorubicin and Cyclophosphamide) (N=82) | 43 (52.4%) | 33 (40.2%) | 5 (6.1%) | 1 (1.2%) | |||
| Capecitabine (N=123) | 66 (53.7%) | 39 (31.7%) | 12 (9.8%) | 6 (4.9%) | |||
|
| |||||||
| Vs Most Extensive Surgery (N=257) | 0.523 | 0.798 | |||||
| Breast Conserving Surgery (N=117) | 58 (49.6%) | 46 (39.3%) | 9 (7.7%) | 4 (3.4%) | |||
| Full Mastectomy (N=140) | 75 (53.6%) | 48 (34.3%) | 13 (9.3%) | 4 (2.9%) | |||
|
| |||||||
| Vs Axillary Dissection (N=259) | 0.327 | 0.475 | |||||
| No (N=56) | 32 (57.1%) | 16 (28.6%) | 6 (10.7%) | 2 (3.6%) | |||
| Yes (N=203) | 101 (49.8%) | 80 (39.4%) | 16 (7.9%) | 6 (3.0%) | |||
|
| |||||||
| Vs RT (N=245) | 0.074 | 0.556 | |||||
| No (N=109) | 63 (57.8%) | 35 (32.1%) | 9 (8.3%) | 2 (1.8%) | |||
| Yes (N=136) | 63 (46.3%) | 56 (41.2%) | 11 (8.1%) | 6 (4.4%) | |||
|
| |||||||
| Vs Number of Nodes Examined (N=254) | 0.741 | 0.878 | |||||
| 0-3 (N=44) | 25 (56.8%) | 13 (29.5%) | 4 (9.1%) | 2 (4.5%) | |||
| 4-7 (N=39) | 20 (51.3%) | 14 (35.9%) | 5 (12.8%) | 0 (0%) | |||
| 8+ (N=171) | 86 (50.3%) | 66 (38.6%) | 13 (7.6%) | 6 (3.5%) | |||
|
| |||||||
| AT 24 MONTHS | Overall Arm/Shoulder Pain (N=240) | 136 (56.7%) | 83 (34.6%) | 16 (6.7%) | 5 (2.1%) | ||
|
| |||||||
| Vs Arm (N=240) | 0.069 | 0.104 | |||||
| CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=49) | 24 (50.0%) | 20 (40.8%) | 3 (6.1%) | 2 (4.1%) | |||
| AC (Doxorubicin and Cyclophosphamide) (N=83) | 42 (50.6%) | 30 (36.1%) | 9 (10.8%) | 2 (2.4%) | |||
| Capecitabine (N=108) | 70 (64.8%) | 33 (30.6%) | 4 (3.7%) | 1 (0.9%) | |||
|
| |||||||
| Vs Most Extensive Surgery (N=238) | 0.851 | 0.149 | |||||
| Breast Conserving Surgery (N=108) | 61 (56.5%) | 41 (38.0%) | 5 (4.6%) | 1 (0.9%) | |||
| Full Mastectomy (N=130) | 75 (57.7%) | 41 (31.5%) | 10 (7.7%) | 4 (3.1%) | |||
|
| |||||||
| Vs Axillary Dissection (N=240) | 0.883 | 0.049 | |||||
| No (N=52) | 29 (55.8%) | 22 (42.3%) | 1 (1.9%) | 0 (0%) | |||
| Yes (N=188) | 107 (56.9%) | 61 (32.4%) | 15 (8.0%) | 5 (2.7%) | |||
|
| |||||||
| Vs RT (N=226) | 0.346 | 0.453 | |||||
| No (N=100) | 61 (61.0%) | 30 (30.0%) | 9 (9.0%) | 0 (0%) | |||
| Yes (N=126) | 69 (54.8%) | 49 (38.9%) | 4 (3.2%) | 4 (3.2%) | |||
|
| |||||||
| Vs Number of Nodes Examined (N=236) | 0.788 | 0.229 | |||||
| 0-3 (N=41) | 25 (61.0%) | 15 (36.6%) | 1 (2.4%) | 0 (0%) | |||
| 4-7 (N=39) | 21 (53.9%) | 15 (38.5%) | 2 (5.1%) | 1 (2.6%) | |||
| 8+ (N=156) | 87 (55.8%) | 52 (33.3%) | 13 (8.3%) | 4 (2.6%) | |||